Stroke
Conditions
Interventions
1:Aspirin 100mg administered orally once daily, initiated within 72 hours of symptom onset, continued for 90 days, in conjunction with ticagrelor therapy (a loading dose of 180mg on the first day, fol
0:In patients within 72 hours of symptom onset, indobufen 100mg was administered orally twice daily for 90 days, coupled with ticagrelor therapy (commencing with a single loading dose of 180mg on the
Sponsors
The People's Hospital of Qiannan, Guizhou Province, China
Eligibility
Sex/Gender
All
Age
40 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Age = 40 years; 2.Acute mild ischemic stroke (NIHSS score = 3 at randomization), with time from symptom onset to treatment initiation = 72 hours, or Transient Ischemic Attack (TIA) with an ABCD2 score = 4; 3.Provision of informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with coagulation disorders, malignancies, hematological diseases, or severe hepatic or renal dysfunction. 2. Patients with intracranial hemorrhage diagnosed by head CT or MRI. 3. Patients with a prior definitive diagnosis of multiple sclerosis. 4. Patients with known allergies to aspirin, ticagrelor, or indobufen. 5. Patients with atrial fibrillation or other thromboembolic conditions requiring anticoagulation therapy. 6. Patients planning to undergo surgical procedures within 3 months necessitating medication discontinuation. 7. Patients with a platelet count below 100×109/L prior to randomization. 8. Patients who had gastrointestinal bleeding or underwent open surgery within 3 months preceding randomization. 9. Women of childbearing potential not using contraception, or patients with a positive pregnancy test. 10. Patients with severe cardiac or pulmonary dysfunction and a life expectancy of less than 3 months. 11. Patients concurrently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of stroke; | — |
Secondary
| Measure | Time frame |
|---|---|
| Abdominal pain;Melena;Symptomatic intracranial hemorrhage ;intracranial hemorrhage;Cutaneous ecchymosis;Mortality within 90 days; | — |
Countries
China
Contacts
Public ContactKaiwu Meng
Neurology Department, The people's hospital of QianNan, GuiZhou Province, People's Republic of China.
Outcome results
None listed